Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRANDON J COAKLEY

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1992065858
CMS profile
647809
Location
MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$859.31

31 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $669.33 29
Education $189.98 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRANDON J COAKLEY

NPI 1992065858 · CMS profile ID 647809

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992065858?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRANDON J COAKLEY, NPI 1992065858, CMS profile ID 647809. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992065858?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRANDON J COAKLEY, NPI 1992065858, CMS profile ID 647809. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992065858?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRANDON J COAKLEY, NPI 1992065858, CMS profile ID 647809, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1992065858?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

31 matching records · $859.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 31 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–31 of 31.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Organogenesis Inc. $35.7412/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145423466 CMS
ABBVIE INC. $19.3511/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482109 CMS
GENZYME CORPORATION $20.3511/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139813465 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $17.7610/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152130428 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.9010/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153806130 CMS
ABBVIE INC. $29.9910/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482107 CMS
Regeneron Healthcare Solutions, Inc. $25.6410/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114027485 CMS
Organogenesis Inc. $36.0710/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145423464 CMS
ABBVIE INC. $4.3710/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482105 CMS
ABBVIE INC. $0.5909/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482103 CMS
ABBVIE INC. $11.1209/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482101 CMS
Kerecis Limited $19.7009/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120107367 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $94.9908/30/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152130426 CMS
Janssen Biotech, Inc. $13.6708/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078638585 CMS
ABBVIE INC. $16.7508/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482099 CMS
ABBVIE INC. $6.0207/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482097 CMS
Arcutis Biotherapeutics, Inc. $13.7907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121037584 CMS
ABBVIE INC. $21.0106/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482095 CMS
Tempus AI, Inc $24.4505/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150162802 CMS
ABBVIE INC. $21.7305/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482093 CMS
ABBVIE INC. $7.0804/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482091 CMS
Novartis Pharmaceuticals Corporation $21.7904/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086636751 CMS
UCB, Inc. $22.3304/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143018419 CMS
Janssen Biotech, Inc. $94.9904/12/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078637857 CMS
ABBVIE INC. $19.7803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482089 CMS
Amgen Inc. $32.4003/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117226142 CMS
ABBVIE INC. $22.9203/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103482087 CMS
Regeneron Healthcare Solutions, Inc. $29.7203/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114027483 CMS
Regeneron Healthcare Solutions, Inc. $121.4802/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114027481 CMS
Organogenesis Inc. $24.0802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145423462 CMS
Biofrontera Inc. $12.7501/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091116777 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,707.61 40
PY2020 $79.47 5
PY2021 $825.47 27
PY2022 $684.14 29
PY2023 $2,563.00 41
PY2024 $859.31 31
PY2025 $1,122.83 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $163,282.10 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,327.10 12/17/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228747197
Principal investigator 1 SANOFI US SERVICES INC. $24,115.00 12/15/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226133899
Principal investigator 1 PFIZER INC. $8,930.60 11/26/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228726918
Principal investigator 1 Incyte Corporation $1,707.00 11/21/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240502003
Principal investigator 1 Incyte Corporation $71.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501878
Principal investigator 1 Incyte Corporation $203.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501896
Principal investigator 1 Incyte Corporation $2,553.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501900
Principal investigator 1 Incyte Corporation $2,553.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501905
Principal investigator 1 Incyte Corporation $81.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501913
Principal investigator 1 Incyte Corporation $81.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501918
Principal investigator 1 Incyte Corporation $81.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501922
Principal investigator 1 Incyte Corporation $81.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501926
Principal investigator 1 Incyte Corporation $47.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501938
Principal investigator 1 Incyte Corporation $2,939.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501946
Principal investigator 1 Incyte Corporation $2,939.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501950
Principal investigator 1 Incyte Corporation $2,939.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501955
Principal investigator 1 Incyte Corporation $2,939.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501959
Principal investigator 1 Incyte Corporation $2,939.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501963
Principal investigator 1 Incyte Corporation $2,114.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501967
Principal investigator 1 Incyte Corporation $2,114.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501971
Principal investigator 1 Incyte Corporation $2,114.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501975
Principal investigator 1 Incyte Corporation $2,114.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501980
Principal investigator 1 Incyte Corporation $2,038.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501984
Principal investigator 1 Incyte Corporation $2,038.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501988
Principal investigator 1 Incyte Corporation $104.20 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501992
Principal investigator 1 Incyte Corporation $1,952.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501996
Principal investigator 1 Incyte Corporation $74.00 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240502007
Principal investigator 1 PFIZER INC. $2,798.60 10/31/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228741596
Principal investigator 1 Incyte Corporation $652.00 10/17/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501882
Principal investigator 1 Incyte Corporation $1,620.00 10/17/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501891
Principal investigator 1 Incyte Corporation $75.00 10/17/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240502015
Principal investigator 1 Incyte Corporation $915.00 10/17/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240502018
Principal investigator 1 Incyte Corporation $2,965.00 10/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501886
Principal investigator 1 Incyte Corporation $1,530.00 10/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501909
Principal investigator 1 Incyte Corporation $3,000.00 10/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501930
Principal investigator 1 Incyte Corporation $17,000.00 10/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501934
Principal investigator 1 Incyte Corporation $2,600.00 10/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240501942
Principal investigator 1 Incyte Corporation $720.00 10/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240502000
Principal investigator 1 Incyte Corporation $2,000.00 10/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH-MYRTLE BEACH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240502011
Principal investigator 1 PFIZER INC. $9,308.60 09/24/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228758698
Principal investigator 1 PFIZER INC. $6,510.00 09/10/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228769674
Principal investigator 1 Eli Lilly and Company $9,900.00 08/08/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187876537
Principal investigator 1 Eli Lilly and Company $9,000.00 07/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876543
Principal investigator 1 PFIZER INC. $19,500.00 05/29/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228764854